CO2023016033A2 - Anticuerpos para el tratamiento y prevención de covid-19 y variantes emergentes - Google Patents

Anticuerpos para el tratamiento y prevención de covid-19 y variantes emergentes

Info

Publication number
CO2023016033A2
CO2023016033A2 CONC2023/0016033A CO2023016033A CO2023016033A2 CO 2023016033 A2 CO2023016033 A2 CO 2023016033A2 CO 2023016033 A CO2023016033 A CO 2023016033A CO 2023016033 A2 CO2023016033 A2 CO 2023016033A2
Authority
CO
Colombia
Prior art keywords
antibodies
spike
covid
prevention
treatment
Prior art date
Application number
CONC2023/0016033A
Other languages
English (en)
Inventor
David D Ho
Yaoxing Huang
Manoj S Nair
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of CO2023016033A2 publication Critical patent/CO2023016033A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La materia descrita en la presente se refiere a una proteína de la espícula (S) recombinante de la variante B.1.351.2-7 del virus SARS-CoV-2, las secuencias de nucleótidos de ADN y ARN que codifican la proteína de la espícula recombinante de B.1.351.2-7 y anticuerpos genomanipulados que se unen a la proteína de la espícula de B.1.351.2-7 y neutralizan el virus B.1.351.2-7.
CONC2023/0016033A 2021-04-28 2023-11-23 Anticuerpos para el tratamiento y prevención de covid-19 y variantes emergentes CO2023016033A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181138P 2021-04-28 2021-04-28
PCT/US2022/026516 WO2022232255A2 (en) 2021-04-28 2022-04-27 Antibodies for the treatment and prevention of covid-19 and emerging variants

Publications (1)

Publication Number Publication Date
CO2023016033A2 true CO2023016033A2 (es) 2023-12-11

Family

ID=83847292

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016033A CO2023016033A2 (es) 2021-04-28 2023-11-23 Anticuerpos para el tratamiento y prevención de covid-19 y variantes emergentes

Country Status (13)

Country Link
US (1) US20240228594A1 (es)
EP (1) EP4330279A2 (es)
JP (1) JP2024518151A (es)
KR (1) KR20240001181A (es)
CN (1) CN117616040A (es)
AU (1) AU2022267248A1 (es)
BR (1) BR112023022493A2 (es)
CA (1) CA3218058A1 (es)
CL (1) CL2023003208A1 (es)
CO (1) CO2023016033A2 (es)
IL (1) IL308042A (es)
MX (1) MX2023012879A (es)
WO (2) WO2022232262A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210899B1 (en) * 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
JP2019529418A (ja) * 2016-09-16 2019-10-17 バイオノミックス リミテッド 抗体およびチェックポイント阻害剤の併用療法
CA3152547A1 (en) * 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
AU2020340881A1 (en) * 2020-04-02 2021-10-21 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
IL308042A (en) 2023-12-01
MX2023012879A (es) 2023-11-24
WO2022232262A2 (en) 2022-11-03
WO2022232262A3 (en) 2022-12-01
BR112023022493A2 (pt) 2024-02-15
AU2022267248A1 (en) 2023-11-09
JP2024518151A (ja) 2024-04-25
CN117616040A (zh) 2024-02-27
WO2022232255A3 (en) 2022-12-22
US20240228594A1 (en) 2024-07-11
CA3218058A1 (en) 2022-11-03
CL2023003208A1 (es) 2024-07-05
KR20240001181A (ko) 2024-01-03
WO2022232255A2 (en) 2022-11-03
EP4330279A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
CL2021000997A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno.
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
AR122899A1 (es) Combinación de vacunas
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
PE20171766A1 (es) Oligomeros antisentido de tau y usos de estos
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
PE20220561A1 (es) Metodos para el tratamiento de infeccion de hepatitis b
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
PE20091109A1 (es) Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
BR112016001192A2 (pt) Vacina contra a raiva
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
CU24574B1 (es) Oligonucleótido que contiene una secuencia nucleobase para disminuir la expresión de tau
CL2019000722A1 (es) Nueva vacuna contra la gripe porcina.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
CO2021000914A2 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh
MX2020003464A (es) Molecula de acidos nucleicos para la reduccion del arnm de papd5 y papd7 en el tratamiento de la infeccion de la hepatitis b.
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CL2024000091A1 (es) Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2
CL2022003491A1 (es) Moléculas de anticuerpo contra el virus bk